DDW 2023 "Poster of Distinction": GlycoVision™ Generated Unprecedented Pre-cancer Detection of Advanced Adenoma
hero guy

Now we can see the full spectrum of our health

For 150 years, scientists have known that glycosylation—the process in which complex sugars are attached to proteins—can tell us about the development and progression of disease. Yet, glycosylation's molecular complexity made it nearly impossible to study at scale or apply to our most urgent clinical needs.

Until now.

Discover Glycoproteomics

High-resolution glycoproteomics

InterVenn has developed the first commercially available platform to exponentially improve the speed, scope, and scale of glycoproteomics. Powered by artificial intelligence (AI) and advanced machine learning (ML), GlycoVision™ can do what a human operator would take months to achieve in a matter of minutes.

Explore GlycoVision

The time to know is now

When it comes to identifying cancer, there’s no such thing as too early. In 2023, InterVenn will release GlycoKnow™ Colon, a laboratory-developed test that uses glycoproteomics to pinpoint precursors to colon cancer with a single blood draw, empowering healthcare professionals to work ahead of the onset of disease.

Explore GlycoKnow Colon

Visionary Leadership

InterVenn is the brainchild of visionary leaders from disparate fields who have combined their expertise to prime glycoproteomics for modern-day exploration.

Founded by Nobel Laureate Dr Carolyn Bertozzi, world-class scientist and distinguished professor Dr Carlito Lebrilla, and leading AI/ML expert Aldo Carrascoso, InterVenn is united in our collective vision to create a new era of personalized, predictive, and preventive care.

Meet Our Leaders

Get in touch